Activist Investors Not Feeling the Wall Street Love

A handful of activist favorites have plunged in the market, and another stock recently targeted by an activist has drawn skepticism from one Wall Street analyst.

Stephen Taub October 7, 2015

Wall Street is treating activist investors very cruelly these days. For one thing, activists have watched as the price of one of their longtime favorite stocks, Valeant Pharmaceuticals International, plunged 25 percent in the past two weeks alone. Jeffrey Ubben’s San Francisco–based ValueAct Capital,

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.04 build:2025-12-18 Login